Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 10/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974109 | 0.88 | ERAP2 (0.58) | ERAP2 | |
| SCHEMBL30777647 | 0.87 | GHSR (0.63) | GHSRERAP2 | |
| SCHEMBL31018948 | 0.85 | ERAP2 (0.66) | ERAP2 | |
| SCHEMBL18857368 | 0.85 | GHSR (0.66) | GHSRERAP2 | |
| SCHEMBL31031505 | 0.85 | ERAP2 (0.59) | ERAP2 | |
| SCHEMBL29531178 | 0.85 | ERAP2 (0.71) | ERAP2 | |
| SCHEMBL29581412 | 0.83 | ERAP2 (0.59) | ERAP2 | |
| SCHEMBL30789083 | 0.83 | ERAP2 (0.62) | ERAP2 | |
| SCHEMBL30839328 | 0.83 | ERAP2 (0.73) | ERAP2 | |
| SCHEMBL18854334 | 0.83 | GHSR (0.56) | GHSRERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| WO-2023240046-A2 | MULTI-OMICS ASSESSMENT | PrognomIQ, Inc. (US) | 2023-12-14 | — | — | WO | claimed |
| US-20250388973-A1 | MULTI-OMICS ASSESSMENT | PROGNOMIQ INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3321686-B1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023240046-A2 | MULTI-OMICS ASSESSMENT | PrognomIQ, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20220193127-A1 | IMMUNOTHERAPY FOR OPIOID ADDICTION | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| US-20220088086-A1 | Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388973-A1 | MULTI-OMICS ASSESSMENT | S100A4, APOL1, SAAL1 | GHSR 4516/4885ERAP2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.